Jennewein Biotechnologie GmbH enforces its patents in the field of human milk oligosaccharides against Nestlé in Germany

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH filed a patent infringement
suit with the regional court in Mannheim on January 09, 2020 against Nestlé
Nutrition GmbH and its holding company Nestlé Deutschland AG. Nestlé offers its
infant formula Beba Supreme which contains two human milk oligosaccharides -
unique saccharides naturally occurring in human breast milk only - for sale in
Germany. Pursuant to the findings of Jennewein Biotechnologie, Nestlé uses human
milk oligosaccharides for the manufacturing of its infant formula that are
produced by a process being protected - among other IP rights - by European
Patents EP 2 896 628 and EP 3 131 912 (start of protection: January 22, 2020)
which are thus infringed by Nestlé.

As Nestlé offers its infant food containing human milk oligosaccharides not just
in Germany, Jennewein currently investigates measures against the assumed
infringement of its corresponding foreign patents by the manufacturing of
products such as Illuma, SMA, NAN and Gerber Good Start.

About HMOs:

Human milk oligosaccharides (HMOs) are complex sugar molecules that are only
present in breast milk. Excluding water, they are the third most abundant
constituent of human milk after fats and lactose. More than 200 structurally
different HMOs have been identified. The most abundant HMO is 2?-fucosyllactose,
which is produced by about 80% of all lactating mothers at concentrations of up
to 3 g/L. Scientific studies have shown that HMOs, and 2?fucosyllactose in
particular, have a positive impact on infant health and development. HMOs are
prebiotics, i.e. they specifically promote the growth of beneficial
microorganisms, and at the same time they inhibit the growth of pathogens by
directly and indirectly preventing colonisation. Jennewein Biotechnologie
launched 2?-fucosyllactose onto the global baby food market in 2015, and several
infant milk formulas around the world now contain 2?-fucosyllactose (e.g. Abbott
Similac).

About Jennewein Biotechnologie:

Jennewein Biotechnologie is a leading international industrial biotechnology
company with a range of products in the field of complex oligosaccharides (HMOs)
and rare monosaccharides. The company manufactures an extensive portfolio of
innovative HMO products, such as 2?fucosyllactose, 3-fucosyllactose and
lacto-N-tetraose. These rare sugars are used in the food industry (particularly
infant milk formulas), the pharmaceutical industry, and the cosmetic industry.
The manufacturing process involves state-of-the-art fermentation techniques. In
2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie
a license to market 2?-fucosyllactose in the USA. This was followed in 2017 by
The European Food Safety Authority (EFSA) under the Novel Food Regulation.

Contact:

Dr. Bettina Gutierrez
Phone: +49 2224 98810 797
bettina.gutierrez@jennewein-biotech.de

Additional content: https://www.presseportal.de/pm/77411/4488546
OTS: Jennewein Biotechnologie GmbH

Original-Content von: Jennewein Biotechnologie GmbH, übermittelt durch news aktuell